جست‌وجوی استاد و پژوهشگر

Linda Huangمشاهده پروفایل

استاد

• Cell Biology
• Meiosis
• Yeast Genetics
• +۴ مورد دیگر

Linda Huang is a Professor in the Department of Biology at the University of Massachusetts Boston, where she also serves as the Graduate Program Director. Her expertise lies in cell biology, with a focused research program on meiosis and spore formation in the budding yeast Saccharomyces cerevisiae . Education: PhD in Biology, California Institute of Technology BS in Biology, University of California, Los Angeles, 1988 Education Abroad Program, University of Sussex, England, 1986–87 Research Interests: Linda Huang's research centers on understanding the molecular mechanisms of meiosis and gametogenesis using yeast as a model organism. Her lab investigates how cellular events during meiosis are coordinated, particularly focusing on the regulation of meiotic exit and spore morphogenesis. She employs genetics, molecular biology, and biochemistry to dissect signaling pathways such as the Cdc15-Sps1 cascade, which plays a critical role in cytokinesis and spindle disassembly during meiosis II. Her recent work has contributed to defining a non-canonical Hippo-like pathway that governs key events in meiotic progression, distinguishing it from mitotic regulation. This research has implications for understanding fundamental cell division processes and their regulation in eukaryotic cells. Publications and Contributions: Huang has authored numerous peer-reviewed articles in top-tier journals, focusing on yeast genetics, cell signaling, and meiotic regulation. Her work has been featured in journals such as Genetics , Molecular Biology of the Cell , and Journal of Fungi . She has also contributed to educational materials, including test banks for widely used biology textbooks.

Edward Stitesمشاهده پروفایل

دانشیار

• Cancer Biology
• Systems Biology
• Computational Biology
• +۴ مورد دیگر

Edward Stites, MD, PhD, is an Associate Professor in the Department of Laboratory Medicine and Pathology at Yale School of Medicine. His interdisciplinary research integrates mathematical modeling, computational biology, and experimental methods to study cancer biology, with a focus on RAS protein signaling networks and precision oncology. Education: BS in Mathematics (University of Kentucky, 1998) PhD in Biophysics (University of Virginia, 2008) MD (University of Virginia, 2010) Clinical Pathology Residency (Washington University School of Medicine, 2015) Postdoctoral Fellowship (Translational Genomics Research Institute, 2012) Dr. Stites leads the Stites Lab, which develops computational models to investigate challenging problems in cancer biology. Their primary research themes include: Mathematical modeling of oncogenic signaling pathways (RAS, RAF, GPCR) Computational analysis of cancer mutation frequencies and therapeutic vulnerabilities Systems biology approaches to identify biomarkers for targeted therapies Integrative genomic analyses of tumor evolution and drug resistance His recent publications demonstrate a consistent focus on RAS pathway biology, spanning mechanistic studies of protein conformations to population-level genomic analyses. Research trends include development of combination therapies, computational mutagenesis techniques, and translational applications in precision oncology. Scientific Awards: NIH Director's New Innovator Award (DP2, 2020) DoD Career Development Award (2020) American Lung Association Discovery Award (2020) Melanoma Research Alliance Young Investigator Award (2018) NCI Career Development Award (2017) Randy Pausch Scholar Award (2012) The Stites Lab maintains active collaborations across Yale Cancer Center and receives funding from multiple NIH grants. Current projects focus on developing mathematical frameworks to predict therapeutic responses in RAS-driven cancers and improving cost-effectiveness of precision medicine approaches.

Sharon Campbellمشاهده پروفایل

استاد

• Structural Biology
• Biochemistry
• Biophysics
• +۶ مورد دیگر

Dr. Sharon Campbell is a Gary F. Liebscher Distinguished Professor of Biochemistry and Biophysics at the UNC School of Medicine, University of North Carolina at Chapel Hill, and a member of the UNC Lineberger Comprehensive Cancer Center. Her research focuses on structural and functional studies of RAS oncoproteins, RAS superfamily members, heterotrimeric GTPases, and cell adhesion proteins vinculin/metavinculin, linking their regulation to cancer, cardiovascular, and neurological disorders. Education : PhD, MS in Biochemistry/Biophysics Key Methods : Multidisciplinary structural (X-ray, NMR, computational), biophysical, biochemical, and cell biology approaches Research Interests include: Elucidating RAS/GTPase recognition by regulatory proteins and effectors Investigating how mutations/post-translational modifications alter GTPase activity Identifying inhibitors for aberrant GTPase functions in disease Understanding vinculin-actin force-dependent 'catch bonds' in cell adhesion Exploring RAS protein radical-based regulation by reactive species Recent Article Trends span structural biology, redox signaling, GTPase dynamics, and cancer mechanisms, with subfields like RAS isoform specificity, ubiquitination, mechanobiology, and platinum drug interactions. Scientific Awards : 2023: OGE Mentoring Award 2014: Battle Distinguished Cancer Research Award 2001: Hettleman Award 1998: Jefferson-Pilot Award Advising highlights mentorship of students securing positions at Eli Lilly and receiving prestigious fellowships. Lab achievements include publications in Nature , Science Signaling , and organizing symposia on RAS pathobiology.

• Cancer
• Liver Pathology
• Tumor Suppression
• +۶ مورد دیگر

Professor Alain de Bruin (born 1968) is a distinguished academic at Utrecht University, serving as Professor in the Department of Biomolecular Health Sciences within the Faculty of Veterinary Medicine. Since January 1, 2020, he has been Head of the Department of Biomolecular Health Sciences. His academic journey began with veterinary medicine studies at the University of Hannover in Germany, followed by a PhD from the University of Bern in Switzerland in 1999. After specializing in veterinary pathology and completing a postdoctoral position at Ohio State University, he was appointed professor of pathobiology at Utrecht University in 2005. In 2010, he founded the Netherlands Molecular Pathology Center (UU/UMCG) and became an honorary professor of molecular pathology at the University of Groningen in 2014. Professor de Bruin's research primarily focuses on cancer biology, liver pathology, tumor suppression mechanisms, and aging processes. His expertise includes in vivo modeling, cell cycle analysis, generating transgenic mouse models, pathological analysis of animal disease models, and single-cell transcriptomics. His work centers on proteins that regulate cell proliferation, particularly E2F transcription factors, which he has discovered play critical roles in inhibiting cancer cell growth. His research themes span Life Sciences, Regenerative Medicine, and the Utrecht Platform for Organoid Technology. Analysis of his recent publications reveals a consistent research trajectory centered on cell cycle regulation, particularly the atypical E2F transcription factors (E2F7 and E2F8), and their roles in cancer development, polyploidization, and liver disease. His work demonstrates how these factors influence tumor suppression, angiogenesis, and cellular responses to DNA damage. The publications span multiple disciplines including cancer biology, molecular oncology, hepatology, and regenerative medicine, with applications in both human and veterinary medicine. Professor de Bruin has held significant leadership positions, including chairing the research council (2017-2019) and coordinating the 'Regenerative Medicine, Stem Cells, and Cancer' research program (2013-2019). He serves on the editorial board of 'Frontiers in Cell and Developmental Biology' and participates in review committees for NWO-Rubicon/Veni, the research alliance UTwente/UU/UMCU, and the Comprehensive Cancer Center at Ohio State University. His laboratory work has made significant contributions to understanding how E2F transcription factors regulate cell proliferation, with implications for developing novel cancer therapy strategies. His research on polyploidization mechanisms has provided insights into liver regeneration and tumor development, while his work on senescence has implications for aging-related diseases.

• Protein-Protein Interactions
• Ras Signaling
• NMR Spectroscopy
• +۴ مورد دیگر

Paul D. Adams is a Professor in the Department of Chemistry & Biochemistry at the University of Arkansas, affiliated with the College of Arts & Sciences. His research focuses on protein structure, dynamics, and interactions using advanced biophysical techniques. Professional Affiliations : Arkansas Biosciences Institute, National Organization of Black Chemists and Chemical Engineers, Protein Society, Sigma Xi Scientific Research Society, Arkansas Academy of Sciences, Biophysical Society. Research Interests : Dr. Adams specializes in multidimensional NMR spectroscopy for protein structure determination and dynamics. His work explores intramolecular motions in proteins, biochemical characterization of protein-protein interactions (PPIs), and the impact of small molecule targets on PPIs. Techniques include steady-state and time-resolved fluorescence spectroscopy, isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC), circular dichroism (CD), and post-column amino acid analysis. Publication Trends : His recent articles focus on Ras family GTPases (Cdc42, Ras mutants), copper-binding domains in nonclassical secretion, calorimetry applications in biomolecular interactions, and structural characterization of protein mutants. Keywords span biophysics, cancer biology, and analytical techniques. Scientific Awards : NSF Minority Postdoctoral Fellow Robert C. and Sandra Connor Endowed Faculty Fellow, Fulbright College of Arts and Sciences Teaching : Dr. Adams teaches biochemistry and has contributed to graduate education. His lab supports research training in NMR spectroscopy and biophysical methods.

Matthew J. Lazzaraمشاهده پروفایل

استاد

• Cell Signaling
• Systems Biology
• Targeted Therapeutics for Cancer
• +۳ مورد دیگر

Matthew J. Lazzara is a Professor of Chemical Engineering and Biomedical Engineering at the University of Virginia, with a joint appointment and membership in the UVA Cancer Center. His research combines experimental and computational approaches to study cell signaling in cancer biology. Education - B.S. in Chemical Engineering from the University of Florida (1997), Ph.D. in Chemical Engineering from MIT (2003), postdoctoral research at MIT (2003-2007). Dr. Lazzara's work focuses on understanding the biochemistry of cellular decision-making to design targeted therapies for brain and pancreatic cancers. His lab investigates spatiotemporal regulation of signaling by phosphatases, receptor trafficking, and computational modeling of biological systems. Recent publications highlight his emphasis on overcoming cancer resistance through combination therapies, computational modeling of signaling pathways, and targeting specific mechanisms like SHP2 inhibition and FGFR-SPRY2 bypass signaling. Awards include the S. Reid Warren, Jr. Award and recognition from the AIChE Delaware Valley for teaching excellence. Funding - NIH/National Cancer Institute, American Cancer Society, National Science Foundation grants. Editorial Roles - Editorial board member of Cellular and Molecular Bioengineering. Service - Former National Board and Board of Directors member of the Museum of Science and Industry in Tampa, FL. The Cell Signaling Engineering Lab, located in the Chemical Engineering Building, collaborates with multidisciplinary teams to bridge engineering and biomedical research for innovative cancer treatments.

Seth Parkerمشاهده پروفایل

استادیار

• Cancer Metabolism
• Nutrient Transporter Biology
• Childhood Leukemia
• +۶ مورد دیگر

Dr. Seth Parker is an Assistant Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia Faculty of Medicine . Based at BC Children’s Hospital, his research group deciphers how nutrient transporters and metabolic reprogramming drive diseases such as cancer, with a special focus on childhood leukemia. He combines biochemical assays, molecular biology, and cutting-edge mass-spectrometry platforms to reveal druggable metabolic vulnerabilities. Research Interests Transporter Biology: Discovery and functional characterization of solute carrier (SLC) transporters that dictate nutrient flux in diseased cells. Compartmentalized Metabolism: Development of organelle-specific metabolomics to understand how enzyme isoform localization provides a proliferative advantage to tumors. Pediatric Leukemia: Identification of selective metabolic dependencies in relapsed childhood leukemia and evaluation of transporter-targeted therapies as alternatives to systemic nutrient depletion. Research Output & Trends Across 2020-2024, Dr. Parker has co-authored multiple high-impact studies ( Nature, Cell, Nat Cancer, Cancer Discov ) that collectively map metabolic rewiring in pancreatic cancer, glioma, Ewing sarcoma, and leukemia. A consistent theme is the integration of metabolomics, proteomics, and in vivo models to translate metabolic findings into therapeutic strategies. Scientific Awards No specific awards were listed in the provided text. Training & Mentorship Dr. Parker actively recruits graduate students, post-doctoral fellows, and research associates. His lab website invites prospective trainees to inquire about opportunities in metabolomics, transporter biology, and pediatric cancer research. Labs & Teams The Parker Laboratory is located in the BC Children’s Hospital Research Institute, with access to core facilities for mass spectrometry, flow cytometry, and animal models, fostering collaborative networks across UBC and the BC Cancer Research Centre.

• Cancer Metabolism
• Metabolomics
• Drug Resistance
• +۴ مورد دیگر

Dr. Esther Zaal serves as an Assistant Professor at Utrecht University's Faculty of Veterinary Medicine, Department of Biomolecular Health Sciences, specializing in Cell Biology, Metabolism & Cancer. Her research focuses on the intersection of cellular metabolism and disease mechanisms, particularly in cancer and immunological contexts. Her research interests center on cancer metabolism, with particular emphasis on metabolic reprogramming in malignancies such as multiple myeloma. Dr. Zaal investigates how metabolic pathways influence drug resistance mechanisms and tumor progression. Her work spans immunometabolism, examining how metabolic processes regulate immune cell function, particularly T cells and dendritic cells. She also explores metabolic vulnerabilities in cancer that could serve as therapeutic targets, with significant work on nucleotide synthesis, amino acid metabolism, and lipid metabolism in tumor cells. Analysis of Dr. Zaal's recent publications reveals a consistent focus on metabolic adaptations in disease states. Her work demonstrates how metabolic rewiring occurs in cancer cells to resist therapeutic interventions and how similar processes affect immune cell function in inflammatory conditions. The research shows particular strength in metabolomics approaches and stable isotope tracing techniques to map metabolic fluxes in various disease models. Dr. Zaal actively supervises research projects and collaborates extensively with the Berkers laboratory and other research groups at Utrecht University. Her work bridges basic metabolic research with potential clinical applications, particularly in developing strategies to overcome drug resistance in cancer treatment. She maintains laboratory facilities focused on metabolomics and cell biology research, utilizing patient-derived organoids, cell culture models, and advanced mass spectrometry techniques to investigate metabolic pathways in health and disease.

Zeynep Erson Omayمشاهده پروفایل

استادیار

• Computational Biology
• Genomics
• Epigenomics
• +۶ مورد دیگر

Dr. Zeynep Erson Omay serves as an Assistant Professor in the Department of Neurosurgery and Biomedical Informatics & Data Science at Yale School of Medicine. Her work bridges computational biology with neurosurgical oncology, focusing on precision medicine applications for brain tumors, with particular emphasis on understanding tumor heterogeneity and molecular mechanisms of CNS tumors. Dr. Erson Omay's educational background includes: PhD in Computer Science from Case Western Reserve University (2011) MS in Computer Science from Bilkent University (2005) BS in Computer Science from Bilkent University (2003) Her research focuses on computational analysis of multi-omic datasets to understand tumor heterogeneity, particularly in central nervous system tumors. Dr. Erson Omay specializes in genomic, transcriptomic, and epigenetic profiling of brain tumors, with emphasis on meningiomas, glioblastomas, and rare CNS tumor subtypes. She leads the Erson Lab, which develops bioinformatics approaches to study large datasets and reveal molecular mechanisms in tumor formation, progression, and clinical outlier subgroups. Her work in precision medicine aims to decipher the molecular architecture of individual tumors to guide personalized treatment approaches, with significant contributions to understanding tumor ecosystems and evolutionary patterns in brain cancers. Dr. Erson Omay's scientific contributions span neuro-oncology, computational biology, and precision medicine, with a strong emphasis on translating genomic findings into clinical applications. Her publications demonstrate consistent innovation in applying computational methods to complex neurosurgical problems, with particular focus on tumor heterogeneity, molecular classification, and racial disparities in tumor genomics. Her notable scientific awards include: 10x Genomics 2021 Pilot Award (2022) Mission Bio Tapestri Grant (2022) Case Western Reserve University, Research ShowCASE-Best Poster Award (2007) Dr. Erson Omay actively mentors students and researchers at various levels, including undergraduate students, graduate students, postdocs, and postgraduate associates. She collaborates extensively within Yale's neurosurgery department and across disciplines to advance computational approaches to brain tumor research. Her work is supported by various grants that enable the development of novel bioinformatics platforms for tumor genomic characterization. She leads the Erson Lab, which focuses on three major research areas: Tumor Ecosystem (studying interactions among tumor and immune cells), Tumor Evolution and Heterogeneity (understanding temporal and spatial tumor evolution), and Precision Medicine (applying genomic techniques to personalize brain tumor treatment). The lab employs diverse omics technologies to explore brain tumor biology and develop computational methods for precision medicine applications.

Gerta Hoxhajمشاهده پروفایل

استادیار

• Cancer Metabolism
• Cell Signaling
• Metabolomics
• +۵ مورد دیگر

Gerta Hoxhaj is an Assistant Professor at the Children's Medical Center Research Institute (CRI) at UT Southwestern Medical Center, with secondary appointments in the Departments of Biochemistry and Pediatrics. She leads an active research laboratory focused on understanding the molecular mechanisms of cancer metabolism. Dr. Hoxhaj received her academic training through the following institutions: Bachelor's degree in Molecular Biology, Genetics, and Chemistry from Bogazici University, Istanbul, Turkey Ph.D. in Biochemistry and Cell Signaling from the MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Scotland, UK Dr. Hoxhaj's research program centers on understanding how cancer cells rewire their metabolism to support growth and survival. Her laboratory investigates three fundamental questions: how cells integrate oncogenic signals to regulate metabolic activities; how metabolism is linked to tissue function; and how cells sense metabolite abundance to maintain homeostasis. Using approaches that combine classical biochemistry, metabolomics, cell biology, and mouse models, her team has made significant contributions to understanding the role of cellular reducing power (NADPH) in cancer metabolism, particularly through the regulation of NAD kinase (NADK). Her work has revealed novel connections between PI3K-Akt-mTORC1 signaling and metabolic pathways including nucleotide synthesis and redox balance. Analysis of Dr. Hoxhaj's recent publications shows a strong focus on mitochondrial metabolism, particularly the role of NADPH in powering essential processes like fatty acid synthesis and protein lipoylation. Her research bridges structural biology (with cryo-EM studies of NADK), cellular metabolism, and cancer biology, revealing how metabolic reprogramming supports tumor growth. A consistent theme across her work is the identification of how oncogenic signaling pathways directly regulate specific metabolic enzymes and processes. Dr. Hoxhaj has received numerous prestigious awards and recognitions for her research: Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research V Foundation Scholar American Cancer Society Scholar Pew-Stewart Scholar for Biomedical Science 2025 TAMEST Mary Beth Maddox Award and Lectureship 2024 Vilcek Prize for Creative Promise in Biomedical Science Dr. Hoxhaj mentors a dynamic research team including postdoctoral fellows, Ph.D. students, and research associates. Her laboratory has secured significant funding from multiple sources including the National Institutes of Health, Welch Foundation, CPRIT, and USDA National Institute of Food and Agriculture. Her research on cancer metabolism has important implications for developing new therapeutic strategies targeting metabolic vulnerabilities in cancer cells. The Hoxhaj Laboratory is part of the Genetic and Metabolic Disease Program at CRI, collaborating closely with other researchers at UT Southwestern including those in the Harold C. Simmons Comprehensive Cancer Center. Her team's recent work on mitochondrial NADPH has opened new avenues for understanding how metabolic pathways are rewired in cancer, with potential applications for multiple cancer types.

• Structural Biology
• Biophysics
• Ion Channels
• +۴ مورد دیگر

Stephen B. Long, PhD, is a Member of the Structural Biology Program at Memorial Sloan Kettering Cancer Center (MSKCC), where he directs the Cryo-Electron Microscopy Innovation Laboratory and chairs the Oversight Committee. His research employs structural biology and biophysics to investigate ion channels and membrane-embedded enzymes involved in immune function, vision, cell differentiation, and cancer pathogenesis. Education: BA in Physics, Amherst College (1994) PhD in Biochemistry, Duke University (2001) Postdoctoral training, Rockefeller University (2007) Research Focus: Dr. Long's lab studies atomic-level mechanisms of ion channels (e.g., calcium-activated chloride channels, potassium channels) and enzymes (e.g., RAS methyltransferases, Hedgehog acyltransferase). His work bridges structural insights with therapeutic development for cancer and immune disorders, leveraging cryo-EM and biochemical techniques to reveal fundamental principles of membrane protein function. Publication Trends: Recent articles emphasize cryo-EM structures of ion channels (BEST1, TWIK-2, ASOR) and mitochondrial calcium regulators, with consistent themes in gating mechanisms, drug inhibition, and disease relevance. Interdisciplinary approaches integrate biophysics, pharmacology, and cell biology. Awards: Louise and Allston Boyer Young Investigator Award (2016) Burroughs Wellcome Career Award in Biomedical Sciences (2006–2014) Leadership & Training: Dr. Long mentors graduate students and postdoctoral researchers in the Tri-Institutional Chemical Biology PhD Program and Gerstner Sloan Kettering Graduate School. His lab collaborates extensively with clinical and translational teams at MSKCC.

Katia Sol-Churchمشاهده پروفایل

استاد پژوهشی

• Genomics
• RASopathies
• Cancer Predisposition Syndromes
• +۳ مورد دیگر

Katia Sol-Church is a Research Professor of Pathology at the University of Virginia School of Medicine and serves as the Director of the Genome Analysis & Technology Core within the Office of Research Core Administration. Her academic journey began with a Doctoral Degree in Cellular Biology from Université Paul Sabatier (Toulouse, France) and a Ph.D. in Biomedical Sciences from McGill University (Montreal, Canada). Her research spans genomics , RASopathies , and cancer predisposition syndromes , with a focus on applying omics technologies to enhance biomedical research rigor and reproducibility. She has pioneered discoveries in rare genetic disorders like Costello syndrome and Noonan syndrome, often collaborating with institutions such as Nemours and the University of Virginia. Her publication record reveals a trend toward integrating genomic analysis with clinical applications , including studies on coronary artery disease regulatory mechanisms (2022), auditory neuropathy genetics (2021), and RASopathy phenotyping (2017-2019). Collaborations with teams at UVA, Nemours, and international institutions underscore her interdisciplinary approach. As Director of the UVA Genomics Core, she leads initiatives to advance biomedical research infrastructure , emphasizing scientific reproducibility and clinical genomics across departments like Pathology and Pediatrics.

• Cancer Biology
• Genomics
• Molecular Oncology
• +۳ مورد دیگر

Barry Taylor, PhD is an Assistant Professor in the Department of Epidemiology & Biostatistics at the University of California, San Francisco (UCSF) School of Medicine. His research focuses on understanding the genetic and molecular mechanisms underlying cancer progression, particularly in oncogene-driven cancers such as melanoma and lung cancer. Key areas of interest include the impact of mutant oncogene zygosity, therapeutic resistance mechanisms, and the role of germline variants in cancer pathogenesis. Principal Investigator on multiple NIH grants (R01CA245069, R01CA204749, R01CA207244) studying driver mutations and targeted therapies. Published over 100 articles in high-impact journals like Nature , Nature Genetics , and Cancer Cell . Research highlights include defining BRCA2 reversion mutations under therapy, identifying lineage-specific oncogenic mechanisms, and uncovering evolutionary drivers of drug resistance. His work bridges genomics, epidemiology, and clinical oncology to advance precision medicine strategies. Grants and collaborations emphasize translational research, with studies on genomic instability, tumor evolution, and targeted drug development. Active in collaborative networks such as the PCF/SU2C International Prostate Cancer Dream Team.

Shoib Siddiquiمشاهده پروفایل

مدرس ارشد

• Cancer Biology
• Immunology
• Glycobiology
• +۴ مورد دیگر

Dr. Shoib Siddiqui is a Senior Lecturer at the University of Hertfordshire's School of Life and Medical Sciences, specializing in cancer biology, immunology, and glycobiology. Previously, he held positions at the American University of Ras Al Khaimah and conducted postdoctoral research at UC San Diego under Prof. Ajit Varki. His research focuses on sialic acids, Siglecs, and microRNA mechanisms in cancer, Alzheimer’s, and sepsis. He earned his Ph.D. from ETH Zurich, investigating neuropilin-2 in skin cancer progression. Education: Ph.D. in Vascular Biology, Immunology, and Cancer Biology (ETH Zurich, 2009–2013) M.Sc. in Biotechnology (IIT Bombay, 2008) Research Focus: Dr. Siddiqui’s work explores cancer progression pathways, tumor biomarkers, and novel therapies. Key areas include Siglec-sialoglycan interactions, microRNA targeting, and drug repurposing for colorectal cancer. His recent projects involve developing RNAi therapeutics and inhibitors for Siglec-15. Projects: Fluralaner as a Colorectal Cancer Therapeutic (2026–2027) ADAMTS-7 Inhibition for Coronary Artery Disease (2022) UK-China Mycotoxin Reduction Alliance (2022–2023) Publications: Over 39 peer-reviewed articles in journals like Journal of Clinical Investigation , PNAS , and Blood , with a focus on oncology, glycobiology, and immunology. Recent trends emphasize Siglec-targeted therapies, microRNA networks, and drug repurposing strategies. Awards: No formal awards listed, but noted for impactful publications in high-impact journals. Advising & Grants: Served as Principal Investigator (PI) on RNAi therapeutics and Co-Investigator (CoI) on Siglec-15 and ADAMTS-7 projects. Collaborations span international institutions and cross-disciplinary teams. Labs/Teams: Active in the Biosciences Research Group and Centre for Research in Mechanisms of Disease and Drug Discovery at UH. Collaborates with global researchers in glycobiology and oncology.

Alissa Richmond Armstrongمشاهده پروفایل

استادیار

• Stem Cell Biology
• Developmental Biology
• Cellular Stress Responses
• +۴ مورد دیگر

Dr. Alissa Richmond Armstrong is an Assistant Professor in the Department of Biological Sciences at the University of South Carolina's McCausland College of Arts and Sciences. She leads the Armstrong Laboratory which investigates how inter-organ communication coordinates stem cell responses to nutritional status using Drosophila melanogaster as a model system. Her research focuses on stem cell and developmental biology, particularly examining how adipocyte-derived signals regulate ovarian stem cells in response to dietary changes. This work has implications for understanding obesity-related diseases including diabetes and cancer. Key research areas include: Nutrient sensing pathways in adipocytes Inter-organ communication networks Conserved signaling mechanisms (insulin/TOR pathways) Stem cell lineage responses to physiological state Her publications demonstrate consistent focus on nutrient-stem cell interactions, with recent work (2020-2024) emphasizing Ras/MAPK signaling mechanisms, methodological developments for stem cell analysis, and broader perspectives on nutritional drivers of development. Earlier foundational work established adipocyte amino acid sensing pathways controlling germline stem cells. She maintains an active research program through the Armstrong Lab which utilizes genetic, molecular, and cell biological approaches to investigate remote nutrient sensing in adult stem cell regulation.